News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Xuanzhu Biopharma-B (02575.HK) Presents Phase III Clinical Data of DiLuoAke at AACR
Xuanzhu Biopharma-B (02575.HK) announced that the Group presented, in an oral session at the 2026 American Association for Cancer Research (AACR) Annual Meeting, the results of its...
Reset
Send
The window will close in 5 seconds
Xuanzhu Biopharma-B (02575.HK) Presents Phase III Clinical Data of DiLuoAke at AACR
Close
Recommend
2
Positive
2
Negative
4
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Gold ETF share!

Xuanzhu Biopharma-B (02575.HK)  +0.100 (+0.529%)   announced that the Group presented, in an oral session at the 2026 American Association for Cancer Research (AACR) Annual Meeting, the results of its Phase III clinical study of DiLuoAke as a first-line treatment for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). The data demonstrated that DiLuoAke showed statistically significant and clinically meaningful efficacy advantages in the first-line treatment of ALK-positive advanced NSCLC.

DiLuoAke tablets (brand name: Xuan Fei Ning? are a next-generation oral ALK inhibitor independently developed by the Group, specifically designed for the treatment of ALK-rearranged advanced non-small cell lung cancer. (de/d)(HK stocks quote is delayed for at least 15 mins.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.